Conventional GnRH antagonist protocols represent a safer and more cost-effective choice for PCOS women undergoing IVF/ICSI cycles than the standard Long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The gene discussed is GNRH1; the disease is polycystic ovary syndrome.